Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (3,666)	$ (2,257)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	334	252
Changes in operating assets and liabilities:
Income tax receivable	(33)	(113)
Prepaid expenses and other current assets	(89)	100
Deposits held for clinical trial costs	(2,561)	0
Accounts payable	3,030	334
Accrued liabilities	(1,498)	(281)
Net cash used in operating activities	(4,483)	(1,965)
Cash flows from financing activities:
Proceeds from exercise of stock purchase warrants	0	1,042
Net cash provided by financing activities	0	1,042
Effect of exchange rate changes on cash	2	(1)
Net change in cash	(4,481)	(924)
Cash and cash equivalents at beginning of period	11,867	9,022
Cash and cash equivalents at end of period	7,386	8,098
Supplemental disclosure of cash flow information:
Cash paid during period for interest	$ 3	$ 3